Hengrui Pharma and GSK plc have entered into strategic agreements to develop up to 12 innovative medicines, with a focus on Respiratory, Immunology & Inflammation, and Oncology. The collaboration includes a $500 million upfront fee and an exclusive license for HRS-9821, a promising treatment for COPD. HRS-9821 has shown potent inhibition of PDE3 and PDE4, offering bronchodilation and anti-inflammatory effects. The agreements also include a scaled collaboration for up to 11 more programs, with Hengrui leading early-stage development and GSK retaining exclusive rights for global commercialization.

The partnership between Hengrui Pharma and GSK plc aims to develop innovative medicines and advance globalization efforts. The strategic agreements include an exclusive license for HRS-9821, a promising treatment for COPD, with potent inhibition of PDE3 and PDE4. The collaboration also features a scaled approach to develop up to 11 more programs, with Hengrui leading early-stage development and GSK retaining rights for global commercialization. This partnership creates new growth opportunities beyond 2031 and complements GSK’s current pipeline in key therapeutic areas.

Read more at Nasdaq: Hengrui Pharma And GSK Collaborate To Advance 12 Next-Gen Drugs In Key Therapeutic Areas